GlassScriptPhysician profile
Alec Frederick Macdonald
NPI 1073956371
$1,053.40
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.63 · 2022: $148 · 2023: $356 · 2024: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.57 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $100.35 | 2023-2024 | |
| Alkermes, INC. | $83.56 | 2022 | |
| Dexcom, INC. | $69.97 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $69.91 | 2022-2023 | Gattex, Trintellix |
| Otsuka America Pharmaceutical, INC. | $63.22 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $61.62 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.78 | 2023-2024 | Ofev, Tradjenta, Jardiance |
| Abbvie INC. | $42.92 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $37.83 | 2023-2024 | Gardasil 9, Proquad, Vaxelis |
| Abbott Laboratories | $30.46 | 2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $28.23 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $27.68 | 2023-2024 | Farxiga |
| Lundbeck LLC | $26.29 | 2024 | Rexulti |
| Indivior INC. | $22.26 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.61 | 2024 | Cologuard Collection Kit |
| Orexo US, INC. | $21.41 | 2024 | Zubsolv |
| Dynavax Technologies Corporation | $21.21 | 2023 | Heplisav-B |
| Abiomed | $20.56 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.06 | 2024 | Caplyta |
| Esperion Therapeutics, INC. | $18.80 | 2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $18.61 | 2023 | |
| Bioventus LLC | $18.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.90 | 2024 | Spravato |
| Amgen INC. | $14.77 | 2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.